Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

XPHOZAH

TENAPANOR HYDROCHLORIDE

Standard Dose
EQ 10MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview XPHOZAH is listed in Drugs@FDA under application 213931 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient TENAPANOR HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 10MG BASE Sponsor ARDELYX INC Submission history Latest submission status date: 2025-06-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview XPHOZAH is listed in Drugs@FDA under application 213931 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient TENAPANOR HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 10MG BASE Sponsor ARDELYX INC Submission history Latest submission status date: 2025-06-16 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
XPHOZAH (TENAPANOR HYDROCHLORIDE) | Drug Monograph | MedicHelpline